title: [Postnatal corticosteroids in preterm infants with immature lung disease].
abstract: BACKGROUND
  Corticosteroids have been used in preterm infants with immature lungs to decrease their need for supplemental oxygen and mechanical ventilation. Whether the benefits of the treatment outweigh possible adverse effects remains controversial. The main objective of the study was to evaluate the effects of intravenous and inhalation corticosteroids on preterm infants' need for supplemental oxygen and mechanical ventilation and potential adverse effects.
  
  
  METHODS
  This was a retrospective cohort study on preterm infants at the Neonatal Intensive Care Unit of Children's Hospital Iceland, born between 2000-2014 and treated with intravenous (n=28) or inhalation (n=30) corticosteroids for immature lung disease. For each infant receiving steriods one infant who did not receive steriods was selected as control, matched on gestational age.
  
  
  RESULTS
  There was a significant decrease in the need for supplemental oxygen following intravenous and inhalation corticosteroids administration, and a significant decrease in the need for mechanical ventilation following intravenous corticosteroids administration, but not in controls. Infants receiving intravenous corticosteroids gained significantly less weight than controls during treatment, but no significant difference in weight between groups was found at 35 weeks postmenstrual age, or in other possible adverse effects such as the prevalence of cerebral palsy.
  
  
  CONCLUSIONS
  Intravenous and inhalation corticosteroids decrease the need for supplemental oxygen in preterm infants with immature lung disease and intravenous steriods facilitate earlier weaning from mechanical ventilation, without significant adverse effects. Therefore, it seems justifiable in selected cases to use corticosteroids in treatment of preterm infants with severe immature lung disease.
  
  
  BACKGROUND
  Corticosteroids, preterm infants, chronic lung disease, mechanical ventilation. Correspondence: Thorður Thorkelsson, thordth@landspitali.is.
authors.forename: Erna
authors.initials: E
authors.lastname: Hinriksdottir
authors.forename: Hrolfur
authors.initials: H
authors.lastname: Brynjarsson
authors.forename: Thordur
authors.initials: T
authors.lastname: Thorkelsson
mesh_terms: D000280:Administration, Inhalation; D061605:Administration, Intravenous; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage* / Q000009:adverse effects; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005260:Female; D005865:Gestational Age; D006776:Hospitals, Pediatric; D006801:Humans; D007055:Iceland; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D008168:Lung / Q000187:drug effects* / Q000503:physiopathology; D008171:Lung Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D010102:Oxygen Inhalation Therapy; D012121:Respiration, Artificial; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D015300:Ventilator Weaning
chemical_list: D000305:Adrenal Cortex Hormones